Agent for treating retinopathy
It is to provide an agent for treating and/or ameliorating retinopathy caused by glucose. It is an agent for treating retinopathy caused by glucose comprising sodium/glucose cotransporter2 inhibitor (SGLT2 inhibitor) as an active ingredient, and is used at a normal dosage amount, or at a lower dosage whereby no lowering in blood sugar is observed.
1. A method for treating retinopathy caused by glucose, comprising administering to a patient in need thereof a composition containing sodium/glucose co-transporter2 inhibitor (SGLT2 inhibitor) as an active ingredient, wherein the SGLT2 inhibitor is administered at a dosage so that no lowering in blood sugar is observed upon administration, and wherein the SGLT2 inhibitor is at least one selected from canagliflozin, ipragliflozin, dapagliflozin, luseogliflozin, empagliflozin and tofogliflozin.
2. The method according to claim 1 , wherein the administration is oral administration.
3. The method according to claim 1 , wherein the retinopathy caused by glucose is diabetic retinopathy and/or diabetic macular edema.
4. A method for treating retinopathy caused by glucose, comprising administering to a patient in need thereof a composition containing sodium/glucose co-transporter2 inhibitor (SGLT2 inhibitor) as an active ingredient, wherein the SGLT2 inhibitor is administered at a dosage so that no lowering in blood sugar is observed upon administration, and wherein the SGLT2 inhibitor comprises at least one of, as canagliflozin, at a therapeutic dose of less than 100 mg per day; as ipragliflozin, at a therapeutic dose of less than 50 mg per day; as dapagliflozin, at a therapeutic dose of less than 5 mg per day; as luseogliflozin, at a therapeutic dose of less than 2.5 mg per day; as empagliflozin, at a therapeutic dose of less than 10 mg per day; and, as tofogliflozin, at a therapeutic dose of less than 20 mg per day.
5. The method according to claim 4 , wherein the administration is oral administration.
6. The method according to claim 4 , wherein the retinopathy caused by glucose is diabetic retinopathy and/or diabetic macular edema.
7. A method for treating a patient having retinopathy caused by glucose, comprising administering to the patient a composition containing sodium/glucose co-transporter2 inhibitor (SGLT2 inhibitor) as an active ingredient, to therapeutically treat the retinopathy caused by glucose without showing an antihyperglycemic action, and wherein the SGLT2 inhibitor is at least one selected from canagliflozin, ipragliflozin, dapagliflozin, luseogliflozin, empagliflozin and tofogliflozin.
8. A method for treating a patient having retinopathy caused by glucose, comprising administering to the patient a composition containing sodium/glucose co-transporter2 inhibitor (SGLT2 inhibitor) as an active ingredient, to therapeutically treat the retinopathy caused by glucose without showing an antihyperglycemic action, wherein the retinopathy caused by glucose is diabetic retinopathy and/or diabetic macular edema, and wherein the SGLT2 inhibitor is at least one selected from canagliflozin, ipragliflozin, dapagliflozin, luseogliflozin, empagliflozin and tofogliflozin.
9. The method according to claim 7 , wherein the administration is oral administration.
10. The method according to claim 7 , wherein the retinopathy caused by glucose is diabetic retinopathy.
11. The method according to claim 10 , wherein the administration is oral administration.